Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Politics
Vandana Singh

Quest Diagnostics Secures CDC Contract To Support COVID-19 Research

  • The Centers for Disease Control and Prevention (CDC) has granted a contract to Quest Diagnostics Inc (NYSE:DGX) to perform testing and provide laboratory data analysis to help identify patterns in SARS-COV-2 seroprevalence on a multistate basis. 
  • Quest was awarded the contract following a competitive bid. The total contract value with all options is valued at up to approximately $19.5 million.
  • The new agreement extends and broadens the scope of the company's contributions to the CDC's seroprevalence research.
  • Also Read: Quest Diagnostics Q4 Earnings, FY22 Reflects Lower Demand For COVID-19 Testing Services.
  • Quest to employ its comprehensive menu of COVID-19 antibody test and data analytics services to support population health research across 45 states and Puerto Rico. 
  • The company's serological tests are authorized by the FDA for emergency use and aid in identifying antibodies produced in response to recent or prior infection and/or vaccination. 
  • Quest will provide the data analysis to the CDC in a HIPAA-compliant manner to support public health analysis and reporting. 
  • Price Action: DGX shares closed 0.56% higher at $143.05 during after-hours trading on Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.